Director/PDMR Shareholding | 19-Nov-2024 | 15:30 | RNS |
GLISTEN Trial of Linerixibat Meets Endpoint | 19-Nov-2024 | 07:00 | RNS |
GSK announces overall survival results for Blenrep | 14-Nov-2024 | 07:00 | RNS |
Block listing Interim Review | 13-Nov-2024 | 15:00 | RNS |
Director/PDMR Shareholding | 12-Nov-2024 | 15:30 | RNS |
GSK publishes provisional 2025 dividend dates | 11-Nov-2024 | 15:01 | RNS |
Total Voting Rights | 01-Nov-2024 | 15:00 | RNS |
Director/PDMR Shareholding | 30-Oct-2024 | 14:29 | RNS |
3rd Quarter Results | 30-Oct-2024 | 07:00 | RNS |
New positive Arexvy data in younger adults at risk | 24-Oct-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 17-Oct-2024 | 15:30 | RNS |
Director/PDMR Shareholding | 16-Oct-2024 | 16:09 | RNS |
FDA accepts new drug application for gepotidacin | 16-Oct-2024 | 07:00 | RNS |
Director/PDMR Shareholding | 14-Oct-2024 | 15:30 | RNS |
Positive results of ANCHOR trials of depemokimab | 14-Oct-2024 | 07:00 | RNS |
Currency | UK Pounds |
Share Price | 1,311.00p |
Change Today | 11.00p |
% Change | 0.85 % |
52 Week High | 1,812.50 |
52 Week Low | 1,300.00 |
Volume | 1,116,111 |
Shares Issued | 4,145.10m |
Market Cap | £54,342m |
Beta | 0.56 |
RiskGrade | 129 |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
Strong Buy | 7 |
Buy | 4 |
Neutral | 11 |
Sell | 2 |
Strong Sell | 0 |
Total | 24 |
Latest | Previous | |
---|---|---|
Q3 | Q2 | |
Ex-Div | 15-Nov-24 | 15-Aug-24 |
Paid | 09-Jan-25 | 10-Oct-24 |
Amount | 15.00p | 15.00p |
Time | Volume / Share Price |
12:26 | 9 @ 1,311.00p |
12:26 | 450 @ 1,311.00p |
12:26 | 734 @ 1,311.50p |
12:26 | 440 @ 1,311.00p |
12:26 | 3,450 @ 1,311.00p |
You are here: research